TALPHERA, INC. (TLPH) Files 8-K for Name Change, Nasdaq Listing

TL;DR

**TALPHERA, INC. officially changed its name from AcelRx Pharmaceuticals and is now trading as TLPH on Nasdaq.**

AI Summary

TALPHERA, INC. (formerly AcelRx Pharmaceuticals, Inc.) filed an 8-K on January 9, 2024, to update its company information, including its new name and trading symbol, TLPH, on The Nasdaq Global Market. This filing primarily serves to formally register these changes with the SEC. For investors, this matters because it confirms the company's rebranding and continued listing on a major exchange, which can impact visibility and trading liquidity.

Why It Matters

This filing confirms TALPHERA, INC.'s official name change from AcelRx Pharmaceuticals, Inc. and its continued listing on The Nasdaq Global Market under the new ticker TLPH, ensuring transparency for investors.

Risk Assessment

Risk Level: low — This filing is purely administrative, updating company information and confirming its listing, posing no direct financial risk.

Analyst Insight

A smart investor would note the name and ticker change for TALPHERA, INC. (TLPH) and update their records, understanding this is an administrative update rather than a fundamental business change.

Key Numbers

• $0.001 — par value per share (par value of the Common Stock)

Key Players & Entities

• TALPHERA, INC. (company) — registrant
• AcelRx Pharmaceuticals, Inc. (company) — former name of registrant
• The Nasdaq Global Market (company) — exchange where securities are registered
• TLPH (company) — trading symbol
• January 9, 2024 (date) — date of earliest event reported
• 001-35068 (dollar_amount) — Commission File No.
• $0.001 (dollar_amount) — par value of Common Stock

Forward-Looking Statements

• The company's rebranding to TALPHERA, INC. will lead to increased investor awareness. (TALPHERA, INC.) — medium confidence, target: 2024-12-31

FAQ

Key Financial Figures

• $0.001 — ge on which registered Common Stock , $0.001 par value TLPH The Nasdaq Global Mar

Filing Documents

• acrx20240108_8k.htm (8-K) — 27KB
• ex_613231.htm (EX-3.1) — 7KB
• ex_613232.htm (EX-3.2) — 158KB
• ex_613436.htm (EX-99.1) — 16KB
• ex_613436img001.jpg (GRAPHIC) — 4KB
• 0001437749-24-000938.txt ( ) — 386KB
• tlph-20240109.xsd (EX-101.SCH) — 3KB
• tlph-20240109_def.xml (EX-101.DEF) — 12KB
• tlph-20240109_lab.xml (EX-101.LAB) — 15KB
• tlph-20240109_pre.xml (EX-101.PRE) — 12KB
• acrx20240108_8k_htm.xml (XML) — 3KB

01

Item 7.01 Regulation FD Disclosure.   On January 9, 2024, the Company issued a press release announcing the Name Change and the Symbol Change. The full text of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.   The information in this Item 7.01, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section and shall not deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.   Item 9.01

Financial Statements and Exhibits

Financial Statements and Exhibits.   (d) Exhibits   Exhibit No. Description 3.1 Certificate of Amendment to the Amended and Restated Certificate of Incorporation, dated January 9, 2024 3.2 Amended and Restated Bylaws, dated January 9, 2024 99.1 Press Release, dated January 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)        

SIGNATURES

SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.       Date: January 9, 2024 TALPHERA, INC.           By:   /s/ Raffi Asadorian       Raffi Asadorian       Chief Financial Officer      

View Full Filing

View this 8-K filing on SEC EDGAR